Glioblastoma — frontier options in Florida
Prefer to look first? Browse the live map without signing up.
30 open options
- EXPANDED ACCESSAVAILABLE
Expanded Access to Gallium Maltolate (GaM)
Gallium Maltolate — 3 sites
- TRIALPHASE1RECRUITING
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
ERAS-801 · ABBV-637 · ABBV-155 — 11 sites
- TRIALPHASE2RECRUITING
OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial
Pembrolizumab · Optune GIO® · NeuroBlate® — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Biospecimen Collection · Magnetic Resonance Imaging · Placebo Administration — 36 sites
- TRIALPHASE1RECRUITING
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Biospecimen Collection · Computed Tomography · Intensity-Modulated Radiation Therapy — 43 sites
- TRIALNARECRUITING
A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial
Chemotherapy · Computed Tomography · Internet-Based Intervention — 2 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Biopsy Procedure · Magnetic Resonance Imaging · Radiation Therapy — 128 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Oral repotrectinib (TPX-0005) — 68 sites
- TRIALPHASE1RECRUITING
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
TheraSphere GBM — 9 sites
- TRIALPHASE1RECRUITING
STARLITE for Unresectable High-Grade Gliomas
Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT) · Abacavir · Lamivudine — 1 site
- TRIALPHASE1RECRUITING
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
Everolimus · Trametinib — 17 sites
- TRIALPHASE1 / PHASE2RECRUITING
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
SIACI of cetuximab and bevacizumab — 1 site
- TRIALPHASE2RECRUITING
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
DOC1021 · Tumor resection · Temodar (Temozolomide) — 18 sites
- TRIALPHASE1RECRUITING
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103 — 4 sites
- TRIALPHASE1RECRUITING
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
Allogeneic Adipose-derived Mesenchymal Stem Cells · Biospecimen Collection · Craniotomy — 1 site
- TRIALPHASE3RECRUITING
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
SonoCloud-9 (SC9) · Carboplatin · Lomustine — 56 sites
- EXPANDED ACCESSAVAILABLE
Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221
DCVax-L — 27 sites
- TRIALPHASE2RECRUITING
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
APL-101 Oral Capsules — 35 sites
- TRIALPHASE1RECRUITING
RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1) · RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2) — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
BAY 3713372 — 63 sites
- TRIALPHASE1RECRUITING
Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial
Radiation Therapy · Radiosurgery · Stereotactic Biopsy — 2 sites
- TRIALNARECRUITING
Non-invasive Glioma Characterization Through Molecular Imaging
3T MRI Scanner — 1 site
- TRIALPHASE1RECRUITING
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs) — 2 sites
- TRIALPHASE2RECRUITING
DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
DB107-RRV · DB107-FC — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
MT-125 — 3 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Temozolomide · Lomustine · Regorafenib — 63 sites
- TRIALPHASE2RECRUITING
Study of Olutasidenib and Temozolomide in HGG
Olutasidenib + TMZ — 20 sites
- TRIALPHASE2NOT_YET_RECRUITING
FG001 Near-Infrared Fluorescence Imaging During Tumor Resection in Newly Diagnosed High-Grade Glioma
FG001 — 5 sites
- TRIALPHASE2RECRUITING
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
silevertinib in combination with temozolomide · temozolomide (TMZ) — 31 sites
- TRIALPHASE3RECRUITING
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Optune® device · Temozolomide · Pembrolizumab — 102 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.